Lensar (LNSR) Return on Capital Employed (2020 - 2026)
Lensar's (LNSR) quarterly Return on Capital Employed came in at 32.43% in Q1 2026, down 39.0% year-on-year from 53.17% in Q1 2025, and up 60.09% on a QoQ basis from 81.27% in Q4 2025.
Lensar (LNSR) Return on Capital Employed (2020 - 2026) Analysis & Trends
Lensar (LNSR) has 7 years of Return on Capital Employed data on file, last reported at 32.43% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 39.0% year-over-year to 32.43% in Q1 2026; TTM through Mar 2026 was 32.43%, a 39.0% decrease from a year earlier, with the FY2025 full-year figure at 86.88%, down 6673.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 32.43%, up from 81.27% in the prior quarter.
- Over the last five years, Return on Capital Employed for LNSR reached as high as 18.67% in Q1 2024 and fell as low as 81.27% in Q4 2025.
- Historically, Return on Capital Employed has averaged 36.36% across 5 years, with a median of 32.43% in 2026.
- Across the five-year window, Return on Capital Employed soared 2593 bps in 2023 and sank 5957 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 45.96% in 2022, then jumped by 55 bps to 20.87% in 2023, then dropped by 4 bps to 21.7% in 2024, then tumbled by 275 bps to 81.27% in 2025, then surged by 60 bps to 32.43% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 32.43% in Q1 2026, 81.27% in Q4 2025, and 60.57% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Lensar | 70.05 Mn | 72.73 Mn | 6.38 Mn | -32.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.43% |
| Dec 31, 2025 | -81.27% |
| Sep 30, 2025 | -60.57% |
| Jun 30, 2025 | -35.13% |
| Mar 31, 2025 | -32.05% |
| Dec 31, 2024 | -21.70% |
| Sep 30, 2024 | -24.65% |
| Jun 30, 2024 | -24.59% |
| Mar 31, 2024 | -18.67% |
| Dec 31, 2023 | -20.87% |
| Sep 30, 2023 | -19.80% |
| Jun 30, 2023 | -27.29% |
| Mar 31, 2023 | -40.66% |
| Dec 31, 2022 | -45.96% |
| Sep 30, 2022 | -45.73% |
| Jun 30, 2022 | -48.80% |
| Mar 31, 2022 | -38.00% |
| Dec 31, 2021 | -33.55% |
| Sep 30, 2021 | -36.28% |
| Jun 30, 2021 | -32.37% |